■ 学会名
World Congress of Nephrology 2026

■ 発表日
2026/03/28

■ 筆頭演者
Tatsuhiko Azegami
Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine

■ 共同演者
Hidehiro Kaneko¹,², Yuta Suzuki¹,³, Akira Okada⁴, Toshiyuki Ko¹, Takahiro Jimba¹, Kentaro Ejiri⁵, Atsushi Mizuno⁶, Katsuhito Fujiu¹,², Norifumi Takeda², Hiroyuki Morita², Shinsuke Yuasa⁵, Koichi Node⁷, Masaomi Nangaku⁸, Norihiko Takeda¹, Hideo Yasunaga⁹, Kaori Hayashi¹⁰
1) Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
2) Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.
3) Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
4) Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
5) Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
6) Department of Cardiology, St. Luke’s International Hospital, Tokyo, Japan
7) Department of Cardiovascular Medicine, Saga University, Saga, Japan
8) Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
9) Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
10) Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine

■ 要旨
Introduction
Cardiovascular-Kidney-Metabolic (CKM) syndrome represents the interconnected pathophysiology of cardiovascular, kidney, and metabolic diseases. These conditions share risk factors with cancer, but the association between CKM stage and cancer incidence is unclear. We examined this relationship in a large real-world Japanese cohort.

Methods
Using a nationwide claims and health checkup database (2014–2023), we identified 1,390,901 individuals without prior cancer. Participants were classified into CKM stages 0–4 based on the 2023 American Heart Association framework, incorporating cardiometabolic risk factors, chronic kidney disease, and atherosclerotic cardiovascular disease. The primary outcome was incident cancer (ICD-10 C00–C97). Cox proportional hazards models estimated hazard ratios (HRs) adjusting for demographic, clinical, and lifestyle factors.

Results
During a median 3.4-year follow-up, cancer incidence increased with advancing CKM stage. Adjusted HRs (95% CI) versus Stage 0 were: 1.03 (0.99–1.08) for Stage 1, 1.02 (0.99–1.05) for Stage 2, 1.25 (1.21–1.29) for Stage 3, and 1.30 (1.25–1.35) for Stage 4. Associations were consistent across multiple cancer types and were stronger in men and individuals <65 years. Sensitivity analyses confirmed robustness. Conclusion Higher CKM stage was significantly associated with increased cancer risk. These findings extend the clinical relevance of CKM syndrome to oncology, highlighting the importance of integrated risk stratification and prevention strategies.